The biotechnology industry has a long R&D cycle and high risks. However, with the government’s vigorous support for the biotechnology industry, coupled with technological advancement and new drugs entering clinical trials, the layout of venture capital-controlled biotechnology companies will bear fruit in recent years, and their operations will move forward. In the growth stage, including Diamond Biotechnology Investment (6901-TW) cultivating two new drug companies with more than 30 billion yuan, Shengde (4123-TW) expects to build more than 7 biotech unicorns by 2025.
After the Haoding and Kea cases, the Taiwan biotechnology industry has experienced a sluggish investment in biotechnology factories in the capital market, coupled with the fact that biotechnology companies possess technologies, and the barriers to entry are high, all of which are the reasons why investors are reluctant to invest in the biotechnology industry. The outbreak of the epidemic has shown a retaliatory rebound under the global capital market, but there is still a funding gap.
In addition, the development time of new biotech drugs takes at least 10 years. The overall R&D cycle is long and the R&D process is highly uncertain. In addition to the high risks that investors face, compared with the electronics industry to form an investment holding company, such as ASE Investment and Control Integrated Silicon Products It is not common for biotech investment and control companies to form a semiconductor packaging and testing investment control group, and the General Assembly Investment Control to integrate a number of semiconductor distributors.
As the epidemic accelerates the progress of drug development, biotechnology investment and control companies have also surfaced. Among them, Shengde has transformed into a professional biotechnology investment holding company, and is currently the largest biotechnology investment and control group in China, cultivating and reinvesting more than 20 companies. , including Jiaxing in China (1167-HK), Taiwan’s Changsheng Biotechnology (6712-TW), Bosheng Biomedical (6733-TW), Yongxin (4726-TW) Wait.
In 2008, the company was positioned as a biotechnology industrial bank, investing in Taiwan, China, Hong Kong and the United States, and promoting more than 10 biotechnology and big health companies to enter the capital market. It is expected to build 7-8 biotechnology companies in 2025. Unicorn business.
In addition, the diamond biotechnology investment, which is regarding to land in the cabinet, its profit model is to create a flagship biotechnology company. At present, there are 10 main investment targets and have passed the dark period.6586-TW) and unity (4743-TW) with a market value of more than 30 billion yuan, and more unicorn biotechnology companies will be incubated in the future.
In addition to companies investing heavily in biotechnology companies, the Biotechnology Center will also set up a 2 billion yuan venture capital fund following two years. It has initially planned to recruit more than 100 industry consultants, and select forward-looking biotechnology manufacturers among many biotechnology manufacturers. technology company.
